TACI/TNFRSF13B/CVID Antibody [Alexa Fluor® 350]

• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 350

TACI/TNFRSF13B/CVID Antibody [Alexa Fluor® 350] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TACI/TNFRSF13B
  Ser2-Thr166
  Accession # Q53F36
• Specificity: Detects human TACI in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant mouse TACI and recombinant human BCMA is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

TACI, transmembrane activator and CAML-interactor, is a member of the TNF receptor superfamily. TACI is a type III membrane protein with an extracellular
N‑terminus in the absence of a cleaved signal sequence. The extracellular region of TACI contains two cysteine rich domains. Within the TNFRSF, it shares the highest homology with BCMA. TACI and BCMA have both been shown to bind APRIL and BAFF, members of the TNF ligand superfamily. TACI is expressed on the cell surface of B cells and activated, but not resting, T cells. Analogous to BCMA, data suggests that TACI may play an important role in B cell development, function and regulation. Human TACI is a 293 amino acid (aa) protein consisting of a 166 aa extracellular domain, a 20 aa transmembrane domain, and a 107 aa intracellular domain. Human and mouse TACI share 54% amino acid identity.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.